WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies,...
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. * WuXia293Stable platform maintains stable expression and consistent product quality during long-term c...
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
* Earns CDP's highest rating for supply chain engagement on climate * Adds to other CDP recognition—Water Security A List and leadership score on climate change * Drives sustainability through value chain decarbonization empowerment SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- WuXi Biologics (2269...
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
* Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. * Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance W...
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regional ESG Top-Rated Company for five consecutive years * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading ...
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL * It reduces viscosity by up to 90% while maintaining formulation stability and injectability SHANGHAI, June 30, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), ...
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
* Contributing to United Nations Sustainable Development Goals * Enhancing transparency and effectiveness for corporate governance * Empowering employees and delivering positive impact to communities * Accelerating actions for tackling climate change and promoting environmental stewardship ...
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
* Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals * Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resear...
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors - Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% - As the company's largest operational single-use bioreactor...
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This also marks ...
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
* Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY * Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY toRMB5,396.9 million * Added 151 new integrated projects, including 13 in late-stage and commercial stage ...
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
* Ranking in top 1% of S&P Global CSA Score * Inclusion in Global Yearbook for third consecutive year * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Develop...
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenicE. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients acros...
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by global partners for strong sustainability commitment * Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"...
WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
* Ranked among the top 1% of companies assessed in the pharmaceutical industry * Recognized as a leader in Green CRDMO, driving innovation for a healthier future * Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focus...
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
* Named for second consecutive year named to prestigious DJSI list * Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), t...
